Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.39722 http://scihub22266oqcxt.onion/10.1002/art.39722 C5129491!5129491!27110697     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27110697&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27110697.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Arthritis+Rheumatol 2016 ; 68 (9): 2174-83 Nephropedia Template TP {{tp|p=27110697|t=2016. A Multicenter, Randomized, Double?Blind, Placebo?Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis |pdf=|usr=}}{{27110697}} gab.com Text A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27110697 #FOAvip Objective: To assess the efficacy and safety of sirukumab, an anti?interleukin?6 monoclonal antibody, for the treatment of patients with active lupus nephritis (LN). Methods: Patients with class III or class IV LN (as determined by renal biopsy within 14 months of randomization) who had persistent proteinuria (>0.5 gm/day) despite receiving immunosuppressive therapy and who were being treated with stable doses of a renin?angiotensin system blocker were randomized (5:1) to receive treatment with sirukumab at a dose of 10 mg/kg intravenously (n?=?21) or placebo (n?=?4) every 4 weeks through week 24. The primary end point was the percent reduction in proteinuria (measured as the protein?to?creatinine [P:C] ratio in a 12?hour urine collection) from baseline to week 24. Results: Twenty?five patients were enrolled, of whom 19 (76.0%) completed treatment through week 24 and 6 (24.0%) discontinued the study agent early, with 5 of the 6 discontinuing due to adverse events. At week 24, the median percent change in proteinuria from baseline to week 24 in sirukumab?treated patients was 0.0% (95% confidence interval ?61.8, 39.6). In contrast, the 4 placebo?treated patients showed an increase in proteinuria (median percent reduction ?43.3%) at week 24. Of note, a subset of 5 sirukumab?treated patients had ?50% improvement in their P:C ratio through week 28. In the sirukumab group, 47.6% of patients experienced ?1 serious adverse event through week 40; most were infection?related. No deaths or malignancies occurred. No serious adverse events were observed in the 4 placebo?treated patients. Conclusion: This proof?of?concept study did not demonstrate the anticipated efficacy nor did it demonstrate an acceptable safety profile for sirukumab treatment in this population of patients with active LN receiving concomitant immunosuppressive treatment. Twit Text FOAVip A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27110697 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27110697 #FOAvip English Wikipedia <ref>{{Cite pmid|27110697}}</ref> A Multicenter, Randomized, Double?Blind, Placebo?Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis #MMPMID27110697 Rovin BH; van Vollenhoven RF; Aranow C; Wagner C; Gordon R; Zhuang Y; Belkowski S; Hsu B Arthritis Rheumatol 2016[Sep]; 68 (9): 2174-83 PMID27110697show ga Objective: To assess the efficacy and safety of sirukumab, an anti?interleukin?6 monoclonal antibody, for the treatment of patients with active lupus nephritis (LN). Methods: Patients with class III or class IV LN (as determined by renal biopsy within 14 months of randomization) who had persistent proteinuria (>0.5 gm/day) despite receiving immunosuppressive therapy and who were being treated with stable doses of a renin?angiotensin system blocker were randomized (5:1) to receive treatment with sirukumab at a dose of 10 mg/kg intravenously (n?=?21) or placebo (n?=?4) every 4 weeks through week 24. The primary end point was the percent reduction in proteinuria (measured as the protein?to?creatinine [P:C] ratio in a 12?hour urine collection) from baseline to week 24. Results: Twenty?five patients were enrolled, of whom 19 (76.0%) completed treatment through week 24 and 6 (24.0%) discontinued the study agent early, with 5 of the 6 discontinuing due to adverse events. At week 24, the median percent change in proteinuria from baseline to week 24 in sirukumab?treated patients was 0.0% (95% confidence interval ?61.8, 39.6). In contrast, the 4 placebo?treated patients showed an increase in proteinuria (median percent reduction ?43.3%) at week 24. Of note, a subset of 5 sirukumab?treated patients had ?50% improvement in their P:C ratio through week 28. In the sirukumab group, 47.6% of patients experienced ?1 serious adverse event through week 40; most were infection?related. No deaths or malignancies occurred. No serious adverse events were observed in the 4 placebo?treated patients. Conclusion: This proof?of?concept study did not demonstrate the anticipated efficacy nor did it demonstrate an acceptable safety profile for sirukumab treatment in this population of patients with active LN receiving concomitant immunosuppressive treatment. äA Multicenter, Randomized, Double?Blind, Placebo?Controlled Study to E(epmc).pdf DeepDyve Pubget Overpricing